Newsroom | 45238 results
Sorted by: Latest
-
China’s Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany’s Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment. The submission follows the granting of Priority Review to p...
-
Samenvatting: Innospera Pharma benoemt Dr. Glenn Crater tot Chief Medical Officer ter ondersteuning van de vooruitgang van ING-006 naar de klinische fase toe
MONTREAL--(BUSINESS WIRE)--Innospera Pharma Inc. (“Innospera”), een privébedrijf actief in biotechnologie nabij de klinische fase die gedifferentieerd kleine moleculemodulators van GPR84 en GPR40 ontwikkelt om inflammatoire en metabolische aandoeningen te behandelen, kondigde vandaag de benoeming aan van Dr. Glenn Crater, MD, FCCP tot Chief Medical Officer (CMO). Glenn zal onmiddellijk starten als fractioneel CMO, met de verbintenis om fulltime in dienst te treden wanneer het hoofdproduct van h...
-
Riassunto: Innospera Pharma nomina il dott. Glenn Crater in qualità di Chief Medical Officer per fornire supporto allo sviluppo verso la fase clinica di ING-006
MONTREAL--(BUSINESS WIRE)--Innospera Pharma Inc. ("Innospera"), un'azienda biotecnologica privata vicina alla fase clinica, che sviluppa modulatori differenziati a molecole di piccole dimensioni di GPR84 e GPR40 per il trattamento di malattie infiammatorie e metaboliche, ha annunciato oggi la nomina del dott. Glenn Crater, MD, FCCP in qualità di Chief Medical Officer (CMO). Glenn occuperà la carica da subito come CMO frazionario, con l'impegno di entrare a far parte dell'azienda a tempo pieno n...
-
Innospera Pharma ernennt Dr. Glenn Crater zum Chief Medical Officer zur Unterstützung der klinischen Entwicklung von ING-006
MONTREAL--(BUSINESS WIRE)--Innospera Pharma Inc. („Innospera“), ein privates Biotechnologieunternehmen im fortgeschrittenen klinischen Stadium, das differenzierte niedermolekulare Modulatoren von GPR84 und GPR40 zur Behandlung von Entzündungs- und Stoffwechselerkrankungen entwickelt, gab heute die Ernennung von Dr. Glenn Crater, MD, FCCP, zum Chief Medical Officer (CMO) bekannt. Glenn wird seine Tätigkeit als CMO in Teilzeit sofort aufnehmen und sich vollzeitlich dem Unternehmen widmen, sobald...
-
Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia
BOSTON & SYDNEY--(BUSINESS WIRE)--BERKSHIRE HATHAWAY SPECIALTY INSURANCE LAUNCHES LIFE SCIENCE, BIOTECH & PHARMACEUTICAL (LBP) MANAGEMENT LIABILITY POLICY IN AUSTRALIA...
-
Resumen: Innospera Pharma nombra al Dr. Glenn Crater para el cargo de director médico con el fin de promover el avance de ING-006 hacia el ámbito de la clínica
MONTREAL--(BUSINESS WIRE)--Innospera Pharma Inc. ("Innospera"), empresa privada de biotecnología en fase casi clínica que desarrolla moduladores diferenciados de moléculas pequeñas de GPR84 y GPR40 para tratar enfermedades inflamatorias y metabólicas, ha anunciado hoy el nombramiento del Dr. Glenn Crater (MD, FCCP) como director médico (CMO). Glenn comenzará a ejercer sus funciones de inmediato como CMO fraccional, con el compromiso de incorporarse a tiempo completo cuando el compuesto principa...
-
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, shares positive results from a clinical study published in the peer-reviewed journal Aging Cell, by a team led by Masaya Koshizaka, M.D., Ph.D., Associate Professor, and Koutaro Yokote, M.D., Ph.D., MBA, President of Chiba University, both of the Center for Preventive Medical Sciences, Chib...
-
Samenvatting: Alnylam krijgt goedkeuring van Europese Commissie voor AMVUTTRA® (vutrisiran) voor de behandeling van ATTR amyloïdose met cardiomyopathie
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), het toonaangevende bedrijf op het gebied van RNA-interferentietherapie (RNAi), kondigde vandaag aan dat de Europese Commissie (EC) een goedkeuring heeft verleend voor de behandeling van wildtype of erfelijke transthyretine amyloïdose bij volwassen patiënten met cardiomyopathie (ATTR-CM) als een aanvullende indicatie voor zijn RNAi-weestherapie AMVUTTRA® (vutrisiran). Deze bekendmaking is officieel geldend in de ori...
-
Resilience Provides Customers With Update on CDMO Business Strategy and Manufacturing Footprint
SAN DIEGO & CINCINNATI--(BUSINESS WIRE)--National Resilience (“Resilience”), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today provided an update on its CDMO business strategy and financing in a letter to its customers. The full letter follows: Dear Resilience Customers, Since our founding in 2020, Resilience has focused on improving the pharmaceutical supply chain and providing manufacturers of complex, advanced medicines the ability to pr...
-
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
RAHWAY, N.J.--(BUSINESS WIRE)--U.S. FDA Approves Merck’s ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season...
